Esperion Therapeutics' aggressive commercialization efforts have significantly boosted retail prescriptions and broadened ...

Otsuka’s IV solutions subsidiary, Otsuka Pharmaceutical Factory, is breaking into the North American market with the help of ...

Otsuka Holdings will pay ICU Medical an upfront payment of $200 million. The U.S. IV products market has seen ...

Otsuka Holdings Co (JP:4578) has released an update. Otsuka Pharmaceutical Factory America, a subsidiary of Otsuka Pharmaceutical Factory, has ...

ICU Medical (ICUI) and Otsuka are launching a joint venture focused on boosting IV solutions production and development in North America. Read more here.

ICU Medical (ICUI) and Otsuka Pharmaceutical Factory, global IV solutions manufacturing subsidiary of Otsuka Holdings Co., Ltd., together announce the creation of a joint venture to provide additional ...

USA: An interim analysis of the Phase 3 VISIONARY study revealed that sibeprenlimab achieved a significant and clinically ...

Aurinia Pharmaceuticals Reports Q3 and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development ...

and in a combined form will have a synergistic effect on Otsuka Pharmaceutical's global expansion," commented Otsuka's president, Makoto Inoue. It's the second acquisition made by Otsuka in the ...

It was used for treating multiple myeloma bone disease. In September 2021, Sunovian Pharmaceuticals announced a joint development and collaboration with Otsuka Pharmaceutical Co. This collaboration ...

For these reasons, the instant petition deserves to be allowed. 5. It has been held by this Court in the case of Otsuka ...